{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:27:50Z","timestamp":1793878070041,"version":"4.7.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-01979-4","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:50:27Z","timestamp":1740729027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Advances in GLP-1 receptor agonists for pain treatment and their future potential"],"prefix":"10.1186","volume":"26","author":[{"given":"Yongtao","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengna","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhe","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"1","key":"1979_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther 9(1):234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Ther"},{"key":"1979_CR2","doi-asserted-by":"publisher","unstructured":"D\u2019Alessio D (2016) Is GLP-1 a hormone: whether and when? J Diabetes Investig 7(suppl 1):150\u201355. https:\/\/doi.org\/10.1111\/jdi.12466","DOI":"10.1111\/jdi.12466"},{"issue":"4","key":"1979_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.beem.2009.03.005","volume":"23","author":"R Mentlein","year":"2009","unstructured":"Mentlein R (2009) Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab 23(4):443\u2013452. https:\/\/doi.org\/10.1016\/j.beem.2009.03.005","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"11\u201312","key":"1979_CR4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1055\/s-2004-826160","volume":"36","author":"CF Deacon","year":"2004","unstructured":"Deacon CF (2004) Circulation and degradation of GIP and GLP-1. Horm Metab Res 36(11\u201312):761\u2013765. https:\/\/doi.org\/10.1055\/s-2004-826160","journal-title":"Horm Metab Res"},{"issue":"6","key":"1979_CR5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17(6):819\u2013837. https:\/\/doi.org\/10.1016\/j.cmet.2013.04.008","journal-title":"Cell Metab"},{"key":"1979_CR6","doi-asserted-by":"publisher","unstructured":"Sun L, Zheng ZM, Shao CS, Zhang ZY, Li MW, Wang L, Wang H, Zhao GH, Wang P (2022) Rational design by structural biology of industrializable, long-acting antihyperglycemic GLP-1 receptor agonists. Pharmaceuticals (Basel) 615. https:\/\/doi.org\/10.3390\/ph15060740","DOI":"10.3390\/ph15060740"},{"key":"1979_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fendo.2020.00178","volume":"11","author":"MP Gilbert","year":"2020","unstructured":"Gilbert MP, Pratley RE (2020) GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of Head-to-head clinical trials. Front Endocrinol (Lausanne) 11:178. https:\/\/doi.org\/10.3389\/fendo.2020.00178","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"1979_CR8","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s10555-024-10192-9","volume":"43","author":"SS Ibrahim","year":"2024","unstructured":"Ibrahim SS, Ibrahim RS, Arabi B, Brockmueller A, Shakibaei M, Busselberg D (2024) The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. Cancer Metastasis Rev 43(4):1297\u20131314. https:\/\/doi.org\/10.1007\/s10555-024-10192-9","journal-title":"Cancer Metastasis Rev"},{"key":"1979_CR9","doi-asserted-by":"publisher","unstructured":"Laurindo LF, Barbalho SM, Guiguer EL, da Silva Soares M, de Souza GA, Fidalgo TM, Araujo AC, de Souza Gonzaga HF, de Bortoli Teixeira D, de Silva Ullmann O, Sloan T, Sloan KP LA (2022) GLP-1a: going beyond traditional use. Int J Mol Sci 23(2). https:\/\/doi.org\/10.3390\/ijms23020739","DOI":"10.3390\/ijms23020739"},{"key":"1979_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","volume":"128","author":"NK Smith","year":"2019","unstructured":"Smith NK, Hackett TA, Galli A, Flynn CR (2019) GLP-1: molecular mechanisms and outcomes of a complex signaling system. Neurochem Int 128:94\u2013105. https:\/\/doi.org\/10.1016\/j.neuint.2019.04.010","journal-title":"Neurochem Int"},{"issue":"5","key":"1979_CR11","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.3892\/ijmm.2018.3509","volume":"41","author":"J Ma","year":"2018","unstructured":"Ma J, Shi M, Zhang X, Liu X, Chen J, Zhang R, Wang X, Zhang H (2018) GLP\u20131R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK\/NF\u2013kappaB signaling pathways in streptozotocin\u2013induced diabetic rats. Int J Mol Med 41(5):2977\u20132985. https:\/\/doi.org\/10.3892\/ijmm.2018.3509","journal-title":"Int J Mol Med"},{"issue":"2","key":"1979_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/jnc.14336","volume":"146","author":"PE Moustafa","year":"2018","unstructured":"Moustafa PE, Abdelkader NF, El Awdan SA, El-Shabrawy OA, Zaki HF (2018) Liraglutide ameliorated peripheral neuropathy in diabetic rats: involvement of oxidative stress, inflammation and extracellular matrix remodeling. J Neurochem 146(2):173\u2013185. https:\/\/doi.org\/10.1111\/jnc.14336","journal-title":"J Neurochem"},{"key":"1979_CR13","doi-asserted-by":"publisher","unstructured":"Mohiuddin MS, Himeno T, Inoue R, Miura-Yura E, Yamada Y, Nakai-Shimoda H, Asano S, Kato M, Motegi M, Kondo M, Seino Y, Tsunekawa S, Kato Y, Suzuki A, Naruse K, Kato K, Nakamura J, Kamiya H (2019) Glucagon-like Peptide-1 receptor agonist protects dorsal Root Ganglion neurons against oxidative insult. J Diabetes Res 2019(9426014). https:\/\/doi.org\/10.1155\/2019\/9426014","DOI":"10.1155\/2019\/9426014"},{"key":"1979_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.bbr.2012.09.021","volume":"237","author":"RS McIntyre","year":"2013","unstructured":"McIntyre RS, Powell AM, Kaidanovich-Beilin O, Soczynska JK, Alsuwaidan M, Woldeyohannes HO, Kim AS, Gallaugher LA (2013) The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res 237:164\u2013171. https:\/\/doi.org\/10.1016\/j.bbr.2012.09.021","journal-title":"Behav Brain Res"},{"issue":"5","key":"1979_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/00207454.2021.1924707","volume":"133","author":"L Zhang","year":"2023","unstructured":"Zhang L, Zhang W, Tian X (2023) The pleiotropic of GLP-1\/GLP-1R axis in central nervous system diseases. Int J Neurosci 133(5):473\u2013491. https:\/\/doi.org\/10.1080\/00207454.2021.1924707","journal-title":"Int J Neurosci"},{"issue":"13","key":"1979_CR16","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C, Maltete D, Derkinderen P, Houeto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carriere N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O, Group LS (2024) Trial of Lixisenatide in early Parkinson\u2019s disease. N Engl J Med 390(13):1176\u20131185. https:\/\/doi.org\/10.1056\/NEJMoa2312323","journal-title":"N Engl J Med"},{"key":"1979_CR17","doi-asserted-by":"publisher","first-page":"106550","DOI":"10.1016\/j.phrs.2022.106550","volume":"186","author":"KO Kopp","year":"2022","unstructured":"Kopp KO, Glotfelty EJ, Li Y, Greig NH (2022) Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment. Pharmacol Res 186:106550. https:\/\/doi.org\/10.1016\/j.phrs.2022.106550","journal-title":"Pharmacol Res"},{"key":"1979_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","volume":"356","author":"KT Watson","year":"2019","unstructured":"Watson KT, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, McIntyre RS, Roat-Shumway S, Myoraku A, Reiss AL, Rasgon NL (2019) Neural correlates of liraglutide effects in persons at risk for Alzheimer\u2019s disease. Behav Brain Res 356:271\u2013278. https:\/\/doi.org\/10.1016\/j.bbr.2018.08.006","journal-title":"Behav Brain Res"},{"issue":"11","key":"1979_CR19","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/mds.29992","volume":"39","author":"H Tang","year":"2024","unstructured":"Tang H, Lu Y, Okun MS, Donahoo WT, Ramirez-Zamora A, Wang F, Huang Y, Armstrong M, Svensson M, Virnig BA, DeKosky ST, Bian J, Guo J (2024) Glucagon-like Peptide-1 receptor agonists and risk of Parkinson\u2019s Disease in patients with type 2 diabetes: a Population-based Cohort Study. Mov Disord 39(11):1960\u20131970. https:\/\/doi.org\/10.1002\/mds.29992","journal-title":"Mov Disord"},{"issue":"10103","key":"1979_CR20","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T (2017) Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390(10103):1664\u20131675. https:\/\/doi.org\/10.1016\/S0140-6736(17)31585-4","journal-title":"Lancet"},{"key":"1979_CR21","doi-asserted-by":"publisher","first-page":"1033479","DOI":"10.3389\/fendo.2022.1033479","volume":"13","author":"H Du","year":"2022","unstructured":"Du H, Meng X, Yao Y, Xu J (2022) The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer\u2019s disease. Front Endocrinol (Lausanne) 13:1033479. https:\/\/doi.org\/10.3389\/fendo.2022.1033479","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1979_CR22","doi-asserted-by":"publisher","first-page":"970925","DOI":"10.3389\/fnins.2022.970925","volume":"16","author":"N Reich","year":"2022","unstructured":"Reich N, Holscher C (2022) The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: an in-depth review. Front Neurosci 16:970925. https:\/\/doi.org\/10.3389\/fnins.2022.970925","journal-title":"Front Neurosci"},{"issue":"1","key":"1979_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s10194-024-01821-3","volume":"25","author":"W Halloum","year":"2024","unstructured":"Halloum W, Dughem YA, Beier D, Pellesi L (2024) Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review. J Headache Pain 25(1):112. https:\/\/doi.org\/10.1186\/s10194-024-01821-3","journal-title":"J Headache Pain"},{"issue":"15","key":"1979_CR24","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1523\/JNEUROSCI.4703-13.2014","volume":"34","author":"N Gong","year":"2014","unstructured":"Gong N, Xiao Q, Zhu B, Zhang CY, Wang YC, Fan H, Ma AN, Wang YX (2014) Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity. J Neurosci 34(15):5322\u20135334. https:\/\/doi.org\/10.1523\/JNEUROSCI.4703-13.2014","journal-title":"J Neurosci"},{"issue":"6","key":"1979_CR25","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00213-018-5154-7","volume":"236","author":"DA Aykan","year":"2019","unstructured":"Aykan DA, Kesim M, Ayan B, Kurt A (2019) Anti-inflammatory and antinociceptive activities of glucagon-like peptides: evaluation of their actions on serotonergic, nitrergic, and opioidergic systems. Psychopharmacology 236(6):1717\u20131728. https:\/\/doi.org\/10.1007\/s00213-018-5154-7","journal-title":"Psychopharmacology"},{"issue":"11","key":"1979_CR26","doi-asserted-by":"publisher","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","volume":"267","author":"J Eng","year":"1992","unstructured":"Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267(11):7402\u20137405","journal-title":"J Biol Chem"},{"issue":"7","key":"1979_CR27","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1172\/JCI1349","volume":"101","author":"J Schirra","year":"1998","unstructured":"Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M (1998) Exendin(9\u201339)amide is an antagonist of glucagon-like peptide-1(7\u201336)amide in humans. J Clin Invest 101(7):1421\u20131430. https:\/\/doi.org\/10.1172\/JCI1349","journal-title":"J Clin Invest"},{"key":"1979_CR28","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-4233732\/v1","author":"CK Park","year":"2024","unstructured":"Park CK, Go EJ, Jo H, Hwang SM, Rahman MM, Park J, Lee JY, Jo YY, Jung Y, Berta T, Kim YH (2024) GLP-1 and its derived peptides mediate Pain Relief through Direct TRPV1 inhibition without affecting Thermoregulation. Res Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-4233732\/v1","journal-title":"Res Sq"},{"issue":"3","key":"1979_CR29","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s10787-022-00978-0","volume":"30","author":"I Mert","year":"2022","unstructured":"Mert I, Cetinkaya A, Gurler M, Turel CA, Celik H, Torun IE, Turel I (2022) Anti-inflammatory potential of liraglutide, a glucagon-like peptide-1 receptor agonist, in rats with peripheral acute inflammation. Inflammopharmacology 30(3):1093\u20131105. https:\/\/doi.org\/10.1007\/s10787-022-00978-0","journal-title":"Inflammopharmacology"},{"key":"1979_CR30","doi-asserted-by":"publisher","unstructured":"Gateva P, Hristov M, Ivanova N, Vasileva D, Ivanova A, Sabit Z, Bogdanov T, Apostolova S, Tzoneva R (2024) Antinociceptive behavior, glutamine\/glutamate, and neopterin in early-stage streptozotocin-induced diabetic neuropathy in liraglutide-treated mice under a standard or enriched environment. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms251910786","DOI":"10.3390\/ijms251910786"},{"issue":"1","key":"1979_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/bph.12895","volume":"172","author":"H Fan","year":"2015","unstructured":"Fan H, Gong N, Li TF, Ma AN, Wu XY, Wang MW, Wang YX (2015) The non-peptide GLP-1 receptor agonist WB4-24 blocks inflammatory nociception by stimulating beta-endorphin release from spinal microglia. Br J Pharmacol 172(1):64\u201379. https:\/\/doi.org\/10.1111\/bph.12895","journal-title":"Br J Pharmacol"},{"issue":"11","key":"1979_CR32","first-page":"991","volume":"28","author":"Z Hu","year":"2005","unstructured":"Hu Z, Wang Y, Luo G, He L (2005) [Estimation of measurement uncertainty of analytical results for the determination of three active components from Gardenia jasminoides Ellis. By HPLC]. Zhong Yao Cai 28(11):991\u2013994","journal-title":"Zhong Yao Cai"},{"key":"1979_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.neuropharm.2014.04.007","volume":"84","author":"N Gong","year":"2014","unstructured":"Gong N, Fan H, Ma AN, Xiao Q, Wang YX (2014) Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors. Neuropharmacology 84:31\u201345. https:\/\/doi.org\/10.1016\/j.neuropharm.2014.04.007","journal-title":"Neuropharmacology"},{"issue":"11","key":"1979_CR34","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1016\/j.apsb.2022.06.003","volume":"12","author":"J Pang","year":"2022","unstructured":"Pang J, Feng JN, Ling W, Jin T (2022) The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs-therapeutic potential exploration in lung injury. Acta Pharm Sin B 12(11):4040\u20134055. https:\/\/doi.org\/10.1016\/j.apsb.2022.06.003","journal-title":"Acta Pharm Sin B"},{"key":"1979_CR35","doi-asserted-by":"publisher","first-page":"1148209","DOI":"10.3389\/fimmu.2023.1148209","volume":"14","author":"SF Mehdi","year":"2023","unstructured":"Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, Nandula SA, Nawaz FK, Tracey K, Yang H, LeRoith D, Brownstein MJ, Roth J (2023) Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol 14:1148209. https:\/\/doi.org\/10.3389\/fimmu.2023.1148209","journal-title":"Front Immunol"},{"key":"1979_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/biomedicines11112990","volume":"11","author":"PG Cho","year":"2023","unstructured":"Cho PG, Jang JH, Ko S, Shin DA, Chung S, Chang MC (2023) The Effect of Evogliptin Tartrate on Controlling Inflammatory Pain. Biomedicines 11:11. https:\/\/doi.org\/10.3390\/biomedicines11112990","journal-title":"Biomedicines"},{"key":"1979_CR37","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.brainresbull.2019.02.001","volume":"147","author":"M Balogh","year":"2019","unstructured":"Balogh M, Varga BK, Karadi DA, Riba P, Puskar Z, Kozsurek M, Al-Khrasani M, Kiraly K (2019) Similarity and dissimilarity in antinociceptive effects of dipeptidyl-peptidase 4 inhibitors, Diprotin A and vildagliptin in rat inflammatory pain models following spinal administration. Brain Res Bull 147:78\u201385. https:\/\/doi.org\/10.1016\/j.brainresbull.2019.02.001","journal-title":"Brain Res Bull"},{"issue":"8","key":"1979_CR38","doi-asserted-by":"publisher","first-page":"635","DOI":"10.7326\/0003-4819-133-8-200010170-00016","volume":"133","author":"DT Felson","year":"2000","unstructured":"Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y, Sowers M, McAlindon T, Spector TD, Poole AR, Yanovski SZ, Ateshian G, Sharma L, Buckwalter JA, Brandt KD, Fries JF (2000) Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 133(8):635\u2013646. https:\/\/doi.org\/10.7326\/0003-4819-133-8-200010170-00016","journal-title":"Ann Intern Med"},{"issue":"7","key":"1979_CR39","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/obr.12173","volume":"15","author":"H Bliddal","year":"2014","unstructured":"Bliddal H, Leeds AR, Christensen R (2014) Osteoarthritis, obesity and weight loss: evidence, hypotheses and horizons - a scoping review. Obes Rev 15(7):578\u2013586. https:\/\/doi.org\/10.1111\/obr.12173","journal-title":"Obes Rev"},{"issue":"5","key":"1979_CR40","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/sj.ijo.0801585","volume":"25","author":"D Coggon","year":"2001","unstructured":"Coggon D, Reading I, Croft P, McLaren M, Barrett D, Cooper C (2001) Knee osteoarthritis and obesity. Int J Obes Relat Metab Disord 25(5):622\u2013627. https:\/\/doi.org\/10.1038\/sj.ijo.0801585","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"4","key":"1979_CR41","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.joca.2010.01.013","volume":"18","author":"W Zhang","year":"2010","unstructured":"Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 18(4):476\u2013499. https:\/\/doi.org\/10.1016\/j.joca.2010.01.013","journal-title":"Osteoarthritis Cartilage"},{"issue":"3","key":"1979_CR42","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.joca.2014.01.003","volume":"22","author":"TE McAlindon","year":"2014","unstructured":"McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin Y, Hunter DJ, Kawaguchi H, Kwoh K, Lohmander S, Rannou F, Roos EM, Underwood M (2014) OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 22(3):363\u2013388. https:\/\/doi.org\/10.1016\/j.joca.2014.01.003","journal-title":"Osteoarthritis Cartilage"},{"key":"1979_CR43","doi-asserted-by":"publisher","unstructured":"Fernandes L, Hagen KB, Bijlsma JW, Andreassen O, Christensen P, Conaghan PG, Doherty M, Geenen R, Hammond A, Kjeken I, Lohmander LS, Lund H, Mallen CD, Nava T, Oliver S, Pavelka K, Pitsillidou I, da Silva JA, de la Torre J, Zanoli G, Vliet Vlieland TP (2013) European League Against R EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis 72(7):1125\u20131135.https:\/\/doi.org\/10.1136\/annrheumdis-2012-202745","DOI":"10.1136\/annrheumdis-2012-202745"},{"issue":"4","key":"1979_CR44","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.21596","volume":"64","author":"MC Hochberg","year":"2012","unstructured":"Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P, American College of R (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 64(4):465\u2013474. https:\/\/doi.org\/10.1002\/acr.21596","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"1979_CR45","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41598-022-05323-7","volume":"12","author":"C Meurot","year":"2022","unstructured":"Meurot C, Martin C, Sudre L, Breton J, Bougault C, Rattenbach R, Bismuth K, Jacques C, Berenbaum F (2022) Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep 12(1):1567. https:\/\/doi.org\/10.1038\/s41598-022-05323-7","journal-title":"Sci Rep"},{"issue":"2","key":"1979_CR46","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41419-017-0217-y","volume":"9","author":"J Chen","year":"2018","unstructured":"Chen J, Xie JJ, Shi KS, Gu YT, Wu CC, Xuan J, Ren Y, Chen L, Wu YS, Zhang XL, Xiao J, Wang DZ, Wang XY (2018) Glucagon-like peptide-1 receptor regulates endoplasmic reticulum stress-induced apoptosis and the associated inflammatory response in chondrocytes and the progression of osteoarthritis in rat. Cell Death Dis 9(2):212. https:\/\/doi.org\/10.1038\/s41419-017-0217-y","journal-title":"Cell Death Dis"},{"issue":"5","key":"1979_CR47","doi-asserted-by":"publisher","first-page":"e024065","DOI":"10.1136\/bmjopen-2018-024065","volume":"9","author":"H Gudbergsen","year":"2019","unstructured":"Gudbergsen H, Henriksen M, Waehrens EE, Overgaard A, Bliddal H, Christensen R, Boesen MP, Knop FKK, Astrup A, Rasmussen MU, Bartholdy C, Daugaard C, Bartels EM, Ellegaard K, Heitmann BL, Kristensen LE (2019) Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial. BMJ Open 9(5):e024065. https:\/\/doi.org\/10.1136\/bmjopen-2018-024065","journal-title":"BMJ Open"},{"issue":"2","key":"1979_CR48","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","volume":"113","author":"H Gudbergsen","year":"2021","unstructured":"Gudbergsen H, Overgaard A, Henriksen M, Waehrens EE, Bliddal H, Christensen R, Nielsen SM, Boesen M, Knop FK, Astrup A, Rasmussen MU, Bartholdy C, Daugaard CL, Ellegaard K, Heitmann BL, Bartels EM, Danneskiold-Samsoe B, Kristensen LE (2021) Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. Am J Clin Nutr 113(2):314\u2013323. https:\/\/doi.org\/10.1093\/ajcn\/nqaa328","journal-title":"Am J Clin Nutr"},{"issue":"9","key":"1979_CR49","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/ard-2023-223845","volume":"82","author":"H Zhu","year":"2023","unstructured":"Zhu H, Zhou L, Wang Q, Cai Q, Yang F, Jin H, Chen Y, Song Y, Zhang C (2023) Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort. Ann Rheum Dis 82(9):1218\u20131226. https:\/\/doi.org\/10.1136\/ard-2023-223845","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1979_CR50","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/17581869.2024.2402214","volume":"14","author":"SS Samajdar","year":"2024","unstructured":"Samajdar SS, Bhaduri G, Ghoshal PK, Mukherjee S, Pal J, Chatterjee N, Joshi SR (2024) Dual effects of dulaglutide on glycemic control and knee osteoarthritis pain in elderly patients with type 2 diabetes. Pain Manag 14(7):365\u2013373. https:\/\/doi.org\/10.1080\/17581869.2024.2402214","journal-title":"Pain Manag"},{"key":"1979_CR51","doi-asserted-by":"publisher","first-page":"108968","DOI":"10.1016\/j.cbi.2020.108968","volume":"322","author":"H Li","year":"2020","unstructured":"Li H, Chen J, Li B, Fang X (2020) The protective effects of dulaglutide against advanced glycation end products (AGEs)-induced degradation of type II collagen and aggrecan in human SW1353 chondrocytes. Chem Biol Interact 322:108968. https:\/\/doi.org\/10.1016\/j.cbi.2020.108968","journal-title":"Chem Biol Interact"},{"issue":"17","key":"1979_CR52","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S, Udden Hemmingsson J, Hjelmesaeth J, Hoffmann Morville T, Koroleva A, Skov Neergaard J, Velez Sanchez P, Wharton S, Wizert A, Kristensen LE, Group SS (2024) Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med 391(17):1573\u20131583. https:\/\/doi.org\/10.1056\/NEJMoa2403664","journal-title":"N Engl J Med"},{"issue":"6","key":"1979_CR53","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1136\/gut.49.6.743","volume":"49","author":"SM Collins","year":"2001","unstructured":"Collins SM, Piche T, Rampal P (2001) The putative role of inflammation in the irritable bowel syndrome. Gut 49(6):743\u2013745. https:\/\/doi.org\/10.1136\/gut.49.6.743","journal-title":"Gut"},{"issue":"1","key":"1979_CR54","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/gut.32.1.73","volume":"32","author":"KW Heaton","year":"1991","unstructured":"Heaton KW, Ghosh S, Braddon FE (1991) How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form. Gut 32(1):73\u201379. https:\/\/doi.org\/10.1136\/gut.32.1.73","journal-title":"Gut"},{"issue":"5","key":"1979_CR55","doi-asserted-by":"publisher","first-page":"e0198024","DOI":"10.1371\/journal.pone.0198024","volume":"13","author":"U Anand","year":"2018","unstructured":"Anand U, Yiangou Y, Akbar A, Quick T, MacQuillan A, Fox M, Sinisi M, Korchev YE, Jones B, Bloom SR, Anand P (2018) Glucagon-like peptide 1 receptor (GLP-1R) expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons. PLoS ONE 13(5):e0198024. https:\/\/doi.org\/10.1371\/journal.pone.0198024","journal-title":"PLoS ONE"},{"issue":"2","key":"1979_CR56","doi-asserted-by":"publisher","first-page":"e13738","DOI":"10.1111\/nmo.13738","volume":"32","author":"R O\u2019Brien","year":"2020","unstructured":"O\u2019Brien R, O\u2019Malley D (2020) The glucagon-like peptide-1 receptor agonist, exendin-4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of irritable bowel syndrome. Neurogastroenterol Motil 32(2):e13738. https:\/\/doi.org\/10.1111\/nmo.13738","journal-title":"Neurogastroenterol Motil"},{"issue":"3","key":"1979_CR57","first-page":"349","volume":"65","author":"Y Yang","year":"2014","unstructured":"Yang Y, Cui X, Chen Y, Wang Y, Li X, Lin L, Zhang H (2014) Exendin-4, an analogue of glucagon-like peptide-1, attenuates hyperalgesia through serotonergic pathways in rats with neonatal colonic sensitivity. J Physiol Pharmacol 65(3):349\u2013357","journal-title":"J Physiol Pharmacol"},{"issue":"4","key":"1979_CR58","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.3892\/mmr.2020.10976","volume":"21","author":"X Cui","year":"2020","unstructured":"Cui X, Zhao X, Wang Y, Yang Y, Zhang H (2020) Glucagon\u2013like peptide\u20131 analogue exendin\u20134 modulates serotonin transporter expression in intestinal epithelial cells. Mol Med Rep 21(4):1934\u20131940. https:\/\/doi.org\/10.3892\/mmr.2020.10976","journal-title":"Mol Med Rep"},{"issue":"1","key":"1979_CR59","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/jgh.13808","volume":"33","author":"T Nozu","year":"2018","unstructured":"Nozu T, Miyagishi S, Kumei S, Nozu R, Takakusaki K, Okumura T (2018) Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats. J Gastroenterol Hepatol 33(1):232\u2013239. https:\/\/doi.org\/10.1111\/jgh.13808","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"1979_CR60","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1365-2036.2008.03870.x","volume":"29","author":"PM Hellstrom","year":"2009","unstructured":"Hellstrom PM, Hein J, Bytzer P, Bjornsson E, Kristensen J, Schambye H (2009) Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 29(2):198\u2013206. https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03870.x","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1979_CR61","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.clinre.2016.12.007","volume":"41","author":"ZY Li","year":"2017","unstructured":"Li ZY, Zhang N, Wen S, Zhang J, Sun XL, Fan XM, Sun YH (2017) Decreased glucagon-like peptide-1 correlates with abdominal pain in patients with constipation-predominant irritable bowel syndrome. Clin Res Hepatol Gastroenterol 41(4):459\u2013465. https:\/\/doi.org\/10.1016\/j.clinre.2016.12.007","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"7","key":"1979_CR62","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/00365521.2022.2041084","volume":"57","author":"AA Touny","year":"2022","unstructured":"Touny AA, Kenny E, Mansson M, Webb DL, Hellstrom PM (2022) Pain relief and pain intensity response to GLP-1 receptor agonist ROSE-010 in irritable bowel syndrome; clinical study cross-analysis with respect to patient characteristics. Scand J Gastroenterol 57(7):783\u2013791. https:\/\/doi.org\/10.1080\/00365521.2022.2041084","journal-title":"Scand J Gastroenterol"},{"issue":"48","key":"1979_CR63","doi-asserted-by":"publisher","first-page":"11701","DOI":"10.1523\/JNEUROSCI.1799-17.2017","volume":"37","author":"HY Wu","year":"2017","unstructured":"Wu HY, Tang XQ, Mao XF, Wang YX (2017) Autocrine Interleukin-10 mediates Glucagon-Like Peptide-1 receptor-Induced spinal microglial beta-endorphin expression. J Neurosci 37(48):11701\u201311714. https:\/\/doi.org\/10.1523\/JNEUROSCI.1799-17.2017","journal-title":"J Neurosci"},{"key":"1979_CR64","doi-asserted-by":"publisher","unstructured":"Ma L, Ju P, Wang W, Wei J, Wang W, Zhao M, Ahmad KA, Wang Y, Chen J (2021) Microglial activation of GLP-1R signaling in Neuropathic Pain promotes Gene expression adaption involved in inflammatory responses. Neural Plast 2021:9923537. https:\/\/doi.org\/10.1155\/2021\/9923537","DOI":"10.1155\/2021\/9923537"},{"key":"1979_CR65","doi-asserted-by":"publisher","first-page":"1342944","DOI":"10.3389\/fnins.2024.1342944","volume":"18","author":"T Noguchi","year":"2024","unstructured":"Noguchi T, Katoh H, Nomura S, Okada K, Watanabe M (2024) The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype. Front Neurosci 18:1342944. https:\/\/doi.org\/10.3389\/fnins.2024.1342944","journal-title":"Front Neurosci"},{"key":"1979_CR66","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ibneur.2023.09.003","volume":"15","author":"S Nomura","year":"2023","unstructured":"Nomura S, Katoh H, Yanagisawa S, Noguchi T, Okada K, Watanabe M (2023) Administration of the GLP-1 receptor agonist exenatide in rats improves functional recovery after spinal cord injury by reducing endoplasmic reticulum stress. IBRO Neurosci Rep 15:225\u2013234. https:\/\/doi.org\/10.1016\/j.ibneur.2023.09.003","journal-title":"IBRO Neurosci Rep"},{"key":"1979_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03355-2","author":"L Maretty","year":"2025","unstructured":"Maretty L, Gill D, Simonsen L, Soh K, Zagkos L, Galanakis M, Sibbesen J, Iglesias MT, Secher A, Valkenborg D, Purnell JQ, Knudsen LB, Tahrani AA, Geybels M (2025) Proteomic changes upon treatment with semaglutide in individuals with obesity. Nat Med. https:\/\/doi.org\/10.1038\/s41591-024-03355-2","journal-title":"Nat Med"},{"issue":"7","key":"1979_CR68","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.4103\/1673-5374.272620","volume":"15","author":"SS Cui","year":"2020","unstructured":"Cui SS, Feng XB, Zhang BH, Xia ZY, Zhan LY (2020) Exendin-4 attenuates pain-induced cognitive impairment by alleviating hippocampal neuroinflammation in a rat model of spinal nerve ligation. Neural Regen Res 15(7):1333\u20131339. https:\/\/doi.org\/10.4103\/1673-5374.272620","journal-title":"Neural Regen Res"},{"key":"1979_CR69","doi-asserted-by":"publisher","first-page":"107463","DOI":"10.1016\/j.nlm.2021.107463","volume":"182","author":"LQ Zhang","year":"2021","unstructured":"Zhang LQ, Zhang W, Li T, Yang T, Yuan X, Zhou Y, Zou Q, Yang H, Gao F, Tian Y, Mei W, Tian XB (2021) GLP-1R activation ameliorated novel-object recognition memory dysfunction via regulating hippocampal AMPK\/NF-kappaB pathway in neuropathic pain mice. Neurobiol Learn Mem 182:107463. https:\/\/doi.org\/10.1016\/j.nlm.2021.107463","journal-title":"Neurobiol Learn Mem"},{"key":"1979_CR70","doi-asserted-by":"publisher","unstructured":"Kuthati Y, Rao VN, Busa P, Wong CS (2021) Teneligliptin exerts Antinociceptive effects in rat model of partial sciatic nerve transection induced neuropathic pain. Antioxid (Basel) 10. https:\/\/doi.org\/10.3390\/antiox10091438","DOI":"10.3390\/antiox10091438"},{"issue":"4","key":"1979_CR71","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/ALN.0000000000000320","volume":"121","author":"B Zhu","year":"2014","unstructured":"Zhu B, Gong N, Fan H, Peng CS, Ding XJ, Jiang Y, Wang YX (2014) Lamiophlomis Rotata, an orally available tibetan herbal painkiller, specifically reduces pain hypersensitivity states through the activation of spinal glucagon-like peptide-1 receptors. Anesthesiology 121(4):835\u2013851. https:\/\/doi.org\/10.1097\/ALN.0000000000000320","journal-title":"Anesthesiology"},{"key":"1979_CR72","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neuropharm.2015.09.010","volume":"101","author":"H Fan","year":"2016","unstructured":"Fan H, Li TF, Gong N, Wang YX (2016) Shanzhiside methylester, the principle effective iridoid glycoside from the analgesic herb Lamiophlomis Rotata, reduces neuropathic pain by stimulating spinal microglial beta-endorphin expression. Neuropharmacology 101:98\u2013109. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.09.010","journal-title":"Neuropharmacology"},{"issue":"7","key":"1979_CR73","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/bph.13720","volume":"174","author":"M Xu","year":"2017","unstructured":"Xu M, Wu HY, Liu H, Gong N, Wang YR, Wang YX (2017) Morroniside, a secoiridoid glycoside from Cornus officinalis, attenuates neuropathic pain by activation of spinal glucagon-like peptide-1 receptors. Br J Pharmacol 174(7):580\u2013590. https:\/\/doi.org\/10.1111\/bph.13720","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1979_CR74","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.bbrc.2020.05.080","volume":"530","author":"X Tang","year":"2020","unstructured":"Tang X, Wu H, Mao X, Li X, Wang Y (2020) The GLP-1 receptor herbal agonist morroniside attenuates neuropathic pain via spinal microglial expression of IL-10 and beta-endorphin. Biochem Biophys Res Commun 530(3):494\u2013499. https:\/\/doi.org\/10.1016\/j.bbrc.2020.05.080","journal-title":"Biochem Biophys Res Commun"},{"key":"1979_CR75","doi-asserted-by":"publisher","unstructured":"Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, Xue H, Liu Y, Zhang Y (2021) GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol (Lausanne) 12721135. https:\/\/doi.org\/10.3389\/fendo.2021.721135","DOI":"10.3389\/fendo.2021.721135"},{"key":"1979_CR76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/brainsci13050789","volume":"13","author":"TCA Belo","year":"2023","unstructured":"Belo TCA, Santos GX, da Silva BEG, Rocha BLG, Abdala DW, Freire LAM, Rocha FS, Galdino G (2023) IL-10\/beta-Endorphin-mediated neuroimmune modulation on Microglia during Antinociception. Brain Sci 13:5. https:\/\/doi.org\/10.3390\/brainsci13050789","journal-title":"Brain Sci"},{"key":"1979_CR77","doi-asserted-by":"publisher","unstructured":"Galiero R, Caturano A, Vetrano E, Beccia D, Brin C, Alfano M, Di Salvo J, Epifani R, Piacevole A, Tagliaferri G, Rocco M, Iadicicco I, Docimo G, Rinaldi L, Sardu C, Salvatore T, Marfella R, Sasso FC (2023) Peripheral neuropathy in diabetes Mellitus: pathogenetic mechanisms and diagnostic options. Int J Mol Sci 24(4). https:\/\/doi.org\/10.3390\/ijms24043554","DOI":"10.3390\/ijms24043554"},{"issue":"6","key":"1979_CR78","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.pmn.2022.05.005","volume":"23","author":"Y Bai","year":"2022","unstructured":"Bai Y, Ma JH, Yu Y, Wang ZW (2022) Effect of cognitive-behavioral therapy or mindfulness therapy on Pain and Quality of Life in patients with Diabetic Neuropathy: a systematic review and Meta-analysis. Pain Manag Nurs 23(6):861\u2013870. https:\/\/doi.org\/10.1016\/j.pmn.2022.05.005","journal-title":"Pain Manag Nurs"},{"key":"1979_CR79","doi-asserted-by":"publisher","first-page":"175896","DOI":"10.1016\/j.ejphar.2023.175896","volume":"954","author":"S Pandey","year":"2023","unstructured":"Pandey S, Mangmool S, Madreiter-Sokolowski CT, Wichaiyo S, Luangmonkong T, Parichatikanond W (2023) Exendin-4 protects against high glucose-induced mitochondrial dysfunction and oxidative stress in SH-SY5Y neuroblastoma cells through GLP-1 receptor\/Epac\/Akt signaling. Eur J Pharmacol 954:175896. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175896","journal-title":"Eur J Pharmacol"},{"key":"1979_CR80","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.neuro.2022.08.007","volume":"92","author":"L Qi","year":"2022","unstructured":"Qi L, Gao R, Chen Z, Lin D, Liu Z, Wang L, Lin L, Liu X, Liu X, Liu L (2022) Liraglutide reduces oxidative stress and improves energy metabolism in methylglyoxal-induced SH-SY5Y cells. Neurotoxicology 92:166\u2013179. https:\/\/doi.org\/10.1016\/j.neuro.2022.08.007","journal-title":"Neurotoxicology"},{"issue":"11","key":"1979_CR81","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1463-1326.2011.01431.x","volume":"13","author":"CG Jolivalt","year":"2011","unstructured":"Jolivalt CG, Fineman M, Deacon CF, Carr RD, Calcutt NA (2011) GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice. Diabetes Obes Metab 13(11):990\u20131000. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01431.x","journal-title":"Diabetes Obes Metab"},{"key":"1979_CR82","doi-asserted-by":"publisher","first-page":"172835","DOI":"10.1016\/j.ejphar.2019.172835","volume":"866","author":"EV Shekunova","year":"2020","unstructured":"Shekunova EV, Kashkin VA, Muzhikyan Acapital AC, Makarova MN, Balabanyan VY, Makarov VG (2020) Therapeutic efficacy of arginine-rich exenatide on diabetic neuropathy in rats. Eur J Pharmacol 866:172835. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172835","journal-title":"Eur J Pharmacol"},{"key":"1979_CR83","doi-asserted-by":"publisher","first-page":"109806","DOI":"10.1016\/j.diabres.2022.109806","volume":"186","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Li Q, Liu S, Zheng H, Ji L, Yi N, Bao W, Zhu X, Sun W, Liu X, Zhang S, Zuo C, Li Y, Xiong Q, Lu B (2022) Glucagon-like peptide-1 receptor agonist attenuates diabetic neuropathic pain via inhibition of NOD-like receptor protein 3 inflammasome in brain microglia. Diabetes Res Clin Pract 186:109806. https:\/\/doi.org\/10.1016\/j.diabres.2022.109806","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"1979_CR84","doi-asserted-by":"publisher","first-page":"108416","DOI":"10.1016\/j.jdiacomp.2023.108416","volume":"37","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhang Q, Bai Y, Zheng H, Ji L, Zhu X, Sun W, Liu X, Zhang S, Li Y, Lu B (2023) Glycogen synthesis kinase-3beta involves in the analgesic effect of liraglutide on diabetic neuropathic pain. J Diabetes Complications 37(3):108416. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108416","journal-title":"J Diabetes Complications"},{"key":"1979_CR85","doi-asserted-by":"publisher","first-page":"123549","DOI":"10.1016\/j.ijpharm.2023.123549","volume":"647","author":"RG Eissa","year":"2023","unstructured":"Eissa RG, Eissa NG, Eissa RA, Diab NH, Abdelshafi NA, Shaheen MA, Elsabahy M, Hammad SK (2023) Oral proniosomal Amitriptyline and liraglutide for management of diabetic neuropathy: exceptional control over hyperglycemia and neuropathic pain. Int J Pharm 647:123549. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.123549","journal-title":"Int J Pharm"},{"key":"1979_CR86","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/cells13221857","volume":"13","author":"SO Lee","year":"2024","unstructured":"Lee SO, Kuthati Y, Huang WH, Wong CS (2024) Semaglutide ameliorates Diabetic Neuropathic Pain by inhibiting Neuroinflammation in the spinal cord. Cells 13:22. https:\/\/doi.org\/10.3390\/cells13221857","journal-title":"Cells"},{"issue":"1","key":"1979_CR87","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1124\/jpet.111.181529","volume":"340","author":"R Bianchi","year":"2012","unstructured":"Bianchi R, Cervellini I, Porretta-Serapiglia C, Oggioni N, Burkey B, Ghezzi P, Cavaletti G, Lauria G (2012) Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy. J Pharmacol Exp Ther 340(1):64\u201372. https:\/\/doi.org\/10.1124\/jpet.111.181529","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"1979_CR88","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1111\/jdi.13544","volume":"12","author":"G Ponirakis","year":"2021","unstructured":"Ponirakis G, Abdul-Ghani MA, Jayyousi A, Zirie MA, Qazi M, Almuhannadi H, Petropoulos IN, Khan A, Gad H, Migahid O, Megahed A, Al-Mohannadi S, AlMarri F, Al-Khayat F, Mahfoud Z, Al Hamad H, Ramadan M, DeFronzo R, Malik RA (2021) Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control. J Diabetes Investig 12(9):1642\u20131650. https:\/\/doi.org\/10.1111\/jdi.13544","journal-title":"J Diabetes Investig"},{"issue":"3","key":"1979_CR89","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00125-023-06072-6","volume":"67","author":"R Dhanapalaratnam","year":"2024","unstructured":"Dhanapalaratnam R, Issar T, Lee ATK, Poynten AM, Milner KL, Kwai NCG, Krishnan AV (2024) Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy. Diabetologia 67(3):561\u2013566. https:\/\/doi.org\/10.1007\/s00125-023-06072-6","journal-title":"Diabetologia"},{"key":"1979_CR90","doi-asserted-by":"publisher","first-page":"1268619","DOI":"10.3389\/fendo.2023.1268619","volume":"14","author":"C Liu","year":"2023","unstructured":"Liu C, Wu T, Ren N (2023) Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy. Front Endocrinol (Lausanne) 14:1268619. https:\/\/doi.org\/10.3389\/fendo.2023.1268619","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1979_CR91","doi-asserted-by":"publisher","first-page":"950623","DOI":"10.3389\/fcell.2022.950623","volume":"10","author":"K Sango","year":"2022","unstructured":"Sango K, Takaku S, Tsukamoto M, Niimi N, Yako H (2022) Glucagon-like Peptide-1 receptor agonists as potential myelination-inducible and anti-demyelinating remedies. Front Cell Dev Biol 10:950623. https:\/\/doi.org\/10.3389\/fcell.2022.950623","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"1979_CR92","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/j.1476-5381.2011.01272.x","volume":"164","author":"WJ Liu","year":"2011","unstructured":"Liu WJ, Jin HY, Lee KA, Xie SH, Baek HS, Park TS (2011) Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br J Pharmacol 164(5):1410\u20131420. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01272.x","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1979_CR93","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.tem.2016.10.001","volume":"28","author":"G Muscogiuri","year":"2017","unstructured":"Muscogiuri G, DeFronzo RA, Gastaldelli A, Holst JJ (2017) Glucagon-like Peptide-1 and the Central\/Peripheral Nervous System: Crosstalk in Diabetes. Trends Endocrinol Metab 28(2):88\u2013103. https:\/\/doi.org\/10.1016\/j.tem.2016.10.001","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"1979_CR94","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s10194-021-01302-x","volume":"22","author":"F Jing","year":"2021","unstructured":"Jing F, Zou Q, Wang Y, Cai Z, Tang Y (2021) Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation. J Headache Pain 22(1):86. https:\/\/doi.org\/10.1186\/s10194-021-01302-x","journal-title":"J Headache Pain"},{"key":"1979_CR95","doi-asserted-by":"publisher","first-page":"137397","DOI":"10.1016\/j.neulet.2023.137397","volume":"812","author":"F Jing","year":"2023","unstructured":"Jing F, Zou Q, Pu Y (2023) GLP-1R agonist liraglutide attenuates pain hypersensitivity by stimulating IL-10 release in a nitroglycerin-induced chronic migraine mouse model. Neurosci Lett 812:137397. https:\/\/doi.org\/10.1016\/j.neulet.2023.137397","journal-title":"Neurosci Lett"},{"issue":"8","key":"1979_CR96","doi-asserted-by":"publisher","first-page":"e14895","DOI":"10.1111\/cns.14895","volume":"30","author":"C Zhou","year":"2024","unstructured":"Zhou C, Zhou Y, Liu L, Jiang H, Wei H, Zhou C, Ji X (2024) Progress and recognition of idiopathic intracranial hypertension: a narrative review. CNS Neurosci Ther 30(8):e14895. https:\/\/doi.org\/10.1111\/cns.14895","journal-title":"CNS Neurosci Ther"},{"key":"1979_CR97","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1126\/scitranslmed.aan0972","volume":"9","author":"HF Botfield","year":"2017","unstructured":"Botfield HF, Uldall MS, Westgate CSJ, Mitchell JL, Hagen SM, Gonzalez AM, Hodson DJ, Jensen RH, Sinclair AJ (2017) A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med 9:404. https:\/\/doi.org\/10.1126\/scitranslmed.aan0972","journal-title":"Sci Transl Med"},{"issue":"1","key":"1979_CR98","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10194-023-01631-z","volume":"24","author":"N Krajnc","year":"2023","unstructured":"Krajnc N, Itariu B, Macher S, Marik W, Harreiter J, Michl M, Novak K, Wober C, Pemp B, Bsteh G (2023) Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain 24(1):89. https:\/\/doi.org\/10.1186\/s10194-023-01631-z","journal-title":"J Headache Pain"},{"issue":"5","key":"1979_CR99","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/brain\/awad003","volume":"146","author":"JL Mitchell","year":"2023","unstructured":"Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Alimajstorovic Z, Greig NH, Li Y, Tsermoulas G, Brock K, Mollan SP, Sinclair AJ (2023) The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain 146(5):1821\u20131830. https:\/\/doi.org\/10.1093\/brain\/awad003","journal-title":"Brain"},{"issue":"7","key":"1979_CR100","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/s41433-023-02908-y","volume":"38","author":"O Grech","year":"2024","unstructured":"Grech O, Mitchell JL, Lyons HS, Yiangou A, Thaller M, Tsermoulas G, Brock K, Mollan SP, Sinclair AJ (2024) Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in idiopathic intracranial hypertension. Eye (Lond) 38(7):1374\u20131379. https:\/\/doi.org\/10.1038\/s41433-023-02908-y","journal-title":"Eye (Lond)"},{"issue":"6","key":"1979_CR101","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11916-024-01215-9","volume":"28","author":"B Heckel","year":"2024","unstructured":"Heckel B (2024) Idiopathic intracranial hypertension after Abrupt Cessation of Medication: a Case Report of Abrupt Glucagon-Like Peptide-1 (GLP-1) receptor Agonist Cessation and Review of the literature. Curr Pain Headache Rep 28(6):453\u2013456. https:\/\/doi.org\/10.1007\/s11916-024-01215-9","journal-title":"Curr Pain Headache Rep"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-01979-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-01979-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-01979-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:50:33Z","timestamp":1740729033000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-01979-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1979"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-01979-4","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of competing interest"}}],"article-number":"46"}}